Prescription drug · ANDA
Capecitabine NDC 16729-072
Capecitabine 150 mg/1 · Tablet, Film coated · Oral · Accord Healthcare Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 16729-072-12 | 1672900721216729007212 | 60 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (16729-072-12)Marketed from Jun 9, 2015 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Capecitabine
- Generic name (nonproprietary)
- capecitabine
- Active ingredients
- Capecitabine — 150 mg/1
- Dosage form
- Tablet, Film coated
- Route
- Oral
- Labeler
- Accord Healthcare Inc.NDC labeler code 16729
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 202593
- Marketing start
- Listing expires
- Other FDA classes
- Nucleic Acid Synthesis Inhibitors (Mechanism)
- Identifiers
- Product ID 16729-072_0e1e6b8e-1e8f-3b26-e063-6294a90ad5fbSPL ID 0e1e6b8e-1e8f-3b26-e063-6294a90ad5fbSPL set ID 8345d55e-ad02-4726-a04b-1a46e3337a4bRxCUI 200327, 200328UNII 6804DJ8Z9U
- Pharmacologic class
- Nucleoside Metabolic Inhibitor
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N416729007212followed by a unit qualifier and the quantityPackage 16729-0072-12. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective . This label includes a boxed warning.
Indications (excerpt from the label)
Capecitabine is a nucleoside metabolic inhibitor indicated for: Colorectal Cancer adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen. ( 1.1 ) perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy. ( 1.1 ) treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen. ( 1.1 ) Breast Cancer treatment of patients with advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated. ( 1.2 ) treatment of patients with ad…
Excerpt only. Read the full label for complete information.
About NDC 16729-072
- What is NDC 16729-072?
- 16729-072 is the product NDC for Capecitabine, Capecitabine 150 mg/1 tablet, film coated, listed with the FDA by Accord Healthcare Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Capecitabine.
- What is the active ingredient?
- Capecitabine.
- Who is the labeler?
- Accord Healthcare Inc., NDC labeler code 16729. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Capecitabine?
- 30 other product NDCs are listed under this name. See all Capecitabine NDCs.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.
Related NDCs: other Capecitabine products
Other finished products listed under the same name: strengths, forms and labelers.
| Product | Strength | Form · route | Labeler | Product NDC | Package NDCs (11-digit) |
|---|---|---|---|---|---|
| Capecitabine | Capecitabine 150 mg/1 | Tablet, Film coatedOral | CivicaScript LLC | 82249-207 | 82249-0207-60 |
| Capecitabine | Capecitabine 500 mg/1 | Tablet, Film coatedOral | CivicaScript LLC | 82249-210 | 82249-0210-12 |
| Capecitabine | Capecitabine 500 mg/1 | Tablet, Film coatedOral | BluePoint Laboratories | 68001-644 | 68001-0644-07 |
| Capecitabine | Capecitabine 150 mg/1 | Tablet, Film coatedOral | BluePoint Laboratories | 68001-643 | 68001-0643-06 |
| capecitabine | Capecitabine 500 mg/1 | Tablet, Film coatedOral | NorthStar RxLLC | 72603-303 | 72603-0303-01 |
| capecitabine | Capecitabine 150 mg/1 | Tablet, Film coatedOral | Camber Pharmaceuticals, Inc. | 31722-774 | 31722-0774-60 |
| capecitabine | Capecitabine 500 mg/1 | Tablet, Film coatedOral | Camber Pharmaceuticals, Inc. | 31722-775 | 31722-0775-1231722-0775-60 |
| Capecitabine | Capecitabine 500 mg/1 | TabletOral | Quallent Pharmaceuticals Health LLC | 82009-112 | 82009-0112-12 |
| Capecitabine | Capecitabine 500 mg/1 | Tablet, Film coatedOral | Cipla USA Inc. | 69097-948 | 69097-0948-08 |
| Capecitabine | Capecitabine 150 mg/1 | Tablet, Film coatedOral | Cipla USA Inc. | 69097-949 | 69097-0949-03 |
Other NDCs under ANDA 202593
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Capecitabine | Capecitabine 500 mg/1 | Tablet, Film coatedOral | Accord Healthcare Inc. | 16729-073 |